Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
Follow-Up Questions
Who is the CEO of ImageneBio Inc?
Dr. Mark Manfredi is the President of ImageneBio Inc, joining the firm since 2016.
What is the price performance of IMA stock?
The current price of IMA is $8.26, it has increased 0.13% in the last trading day.
What are the primary business themes or industries for ImageneBio Inc?
ImageneBio Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is ImageneBio Inc market cap?
ImageneBio Inc's current market cap is $92.3M
Is ImageneBio Inc a buy, sell, or hold?
According to wall street analysts, 2 analysts have made analyst ratings for ImageneBio Inc, including 2 strong buy, 2 buy, 2 hold, 0 sell, and 2 strong sell
